Affiliation:
1. Department of Pediatric Pneumology and Allergology, Faculty of Medicine and University Hospital Carl Gustav Carus Dresden Technische Universität Dresden Dresden Germany
2. Center for Rhinology and Allergy Wiesbaden Germany
3. IQVIA Frankfurt Germany
4. Department of Otorhinolaryngology, Head and Neck Surgery University of Tübingen Tübingen Germany
Abstract
AbstractBackgroundAllergen immunotherapy (AIT) may have a long‐term disease‐modifying effect. The aim of this study was to demonstrate the long‐term effects of pollen allergoid tyrosine‐adsorbed subcutaneous AIT on allergic rhinitis (AR) and asthma (AA) in clinical practice.MethodsThis retrospective study, funded by an AIT manufacturer, analysed the impact of AIT on AR progression and onset of need for AA medication, using a German database covering ~35% of national prescriptions during 2008–2020. Anonymized prescription data of AR patients aged 5–65 years treated with grass or tree pollen AIT between 2009 and 2013 and followed for at least 2 years after AIT cessation were compared with matched control patients with seasonal AR.Results181,496 patients received AIT prescriptions. 5959 fulfilled the inclusion criteria. The median AIT treatment duration was 1092 days and the follow‐up duration was 6.4 years. Less patients treated with AIT received prescriptions for symptomatic AR medication in the follow‐up versus controls (AIT: OR: 0.37; 95% Confidence Interval (CI) 0.34, 0.40; p < .001, tyrosine‐adsorbed AIT: OR: 0.27; 95% CI 0.20, 0.35 p < .001). Less asthmatic patients under AIT received prescriptions for AA medications versus controls (AIT: OR: 0.48; 95% CI 0.41, 0.55; p < .001, tyrosine‐adsorbed AIT: OR: 0.48; 95% CI 0.29, 0.79; p = .004). AR and AA medication prescriptions for AIT patients were reduced in the follow‐up versus baseline and controls (AIT: AR: 20.0%; 1.5 vs. 0.2 prescriptions; AA: 29.1%; 2.0 vs. 0.6 prescriptions, p < .001; tyrosine‐adsorbed AIT: AR: 24.2%, 1.4 vs. 0.2 prescriptions; AA: 35.6%, 2.1 vs. 0.6 prescriptions, p < .001). The probability of AA medication onset in non‐asthmatic patients during follow‐up was reduced for AIT patients compared to controls (OR: 0.77, 95% CI 0.66, 0.90; p = .001). All endpoints were significant for children/adolescents and adults in stratified analyses.ConclusionsWe found evidence for long‐term effects up to 9.5 years for tyrosine‐adsorbed AIT.
Subject
Immunology,Immunology and Allergy